Taysha Gene Therapies, Inc.(TSHA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TSHA Taysha Gene Therapies, Inc.

美国独立日休市 07-02 16:00:00 EDT

6.53

-0.12

-1.80%

盘后6.55

+0.02+0.31%

19:27 EDT

最高6.81	最低6.40	成交量232.55万
今开6.70	昨收6.65	日振幅6.17%
总市值20.89亿	流通市值12.08亿	总股本3.20亿
成交额1,518万	换手率1.26%	流通股本1.85亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":6.53,"timestamp":1783022400000,"preClose":6.65,"halted":0,"volume":2325512,"hourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.53,"latestTime":"19:27 EDT","volume":94269,"amount":615563.7292,"timestamp":1783034842359,"change":0.02,"changeRate":0.003063,"amplitude":0.03026},"delay":0,"changeRate":-0.018045112781954902,"floatShares":185000000,"shares":319861000,"eps":-0.377498,"marketStatus":"美国独立日休市","change":-0.12,"latestTime":"07-02 16:00:00 EDT","open":6.7,"high":6.805,"low":6.395,"amount":15178674.9618,"amplitude":0.061654,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.377498,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":6.65,"preHourTrading":{"tag":"盘前","latestPrice":6.91,"preClose":6.65,"latestTime":"08:41 EDT","volume":66,"amount":447.529962,"timestamp":1782996073990,"change":0.26,"changeRate":0.039098,"amplitude":0.090226},"postHourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.53,"latestTime":"19:27 EDT","volume":94269,"amount":615563.7292,"timestamp":1783034842359,"change":0.02,"changeRate":0.003063,"amplitude":0.03026},"volumeRatio":0.3069115949758657,"impliedVol":0.998,"impliedVolPercentile":0.5777},"requestUrl":"/m/hq/s/TSHA","defaultTab":"news","newsList":[{"id":"1122485138","title":"Taysha Gene Therapies公布多项报告，重点展示其TSHA-102在2026年IRSF Rett综合征科学会议上的临床项目进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1122485138","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122485138?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:02","pubTimestamp":1782417761,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc.宣布，将在2026年国际Rett综合征基金会（IRSF）Rett综合征科学会议上进行多项专题报告，重点介绍其核心候选疗法TSHA-102的临床开发项目。\n这些报告将涵盖临床前及早期临床试验数据，旨在展示TSHA-102在治疗Rett综合征方面的潜力与最新进展。公司计划通过不同形式的展示，深入阐述该基因疗法的研发路径、作用机制以及观察到的生物标志物反应。\n此次科学会议为分享关键研究成果提供了重要平台，有助于推动Rett综合征领域的科学对话与治疗发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107634465","title":"Taysha Gene Therapies启动2亿美元普通股及预融资权证承销公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1107634465","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107634465?lang=zh_cn&edition=full","pubTime":"2026-06-25 04:02","pubTimestamp":1782331335,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. 已启动一项承销公开发行，计划筹集总额高达2亿美元的资金。此次发行将包含公司普通股以及与之配套的预融资权证。\n此举旨在为公司的基因治疗产品管线研发及一般企业用途提供资金支持。发行条款，包括具体价格与数量，将根据市场状况及其他因素最终确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144802167","title":"Taysha Gene Therapies：12个月时，100%的Reveal Part a患者获得或重获发育里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1144802167","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144802167?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:05","pubTimestamp":1782129939,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies公司宣布，其Reveal Part a研究中的所有患者，在12个月时均获得或重获了关键的发育里程碑。这一数据展现了该公司基因疗法在临床开发中的积极进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180909008","title":"Taysha基因疗法公司宣布Reveal关键试验完成给药，并公布评估TSHA-102治疗Rett综合征的Reveal 1/2期试验A部分的长期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1180909008","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180909008?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:01","pubTimestamp":1782129682,"startTime":"0","endTime":"0","summary":"Taysha基因疗法公司宣布，其评估TSHA-102治疗Rett综合征的Reveal关键临床试验已完成患者给药。同时，该公司还公布了来自Reveal 1/2期试验A部分的更长期临床数据。\n该消息标志着Taysha在推进其基因疗法候选药物TSHA-102方面取得了重要进展。关键试验的完成是药物开发过程中的一个关键节点，为后续的数据分析和潜在的监管提交奠定了基础。\n此外，从早期试验阶段获得的更长期数据，有望为TSHA-102的安全性和有效性提供更深入的见解，这对于评估该疗法的持久潜力至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161746135","title":"Taysha Gene Therapies：REVEAL 1/2期试验A部分长期安全性与疗效数据更新预计于2026年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1161746135","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161746135?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:07","pubTimestamp":1767704837,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. 宣布，其针对REVEAL 1/2期临床试验A部分所获得的更长周期安全性与有效性数据更新，预计将在2026年上半年对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100471162","title":"Taysha基因疗法公司在Rett综合征关键基因治疗项目Tsha-102取得重要进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100471162","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100471162?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:06","pubTimestamp":1767704785,"startTime":"0","endTime":"0","summary":"Taysha基因疗法公司宣布，其针对Rett综合征研发的核心基因治疗候选药物Tsha-102在关键项目推进中取得显著进展。该项目的阶段性成果标志着公司在神经系统疾病基因治疗领域迈出坚实一步，为罕见病治疗带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178054298","title":"Taysha基因疗法公司：关键性Reveal试验及Aspire试验给药完成预计于2026年第二季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1178054298","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178054298?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:02","pubTimestamp":1767704564,"startTime":"0","endTime":"0","summary":"Taysha基因疗法公司宣布，其关键性Reveal临床试验以及Aspire试验的给药阶段预计将于2026年第二季度完成。这一进展标志着公司在推进其基因疗法研发项目方面取得了重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517616939","title":"Taysha Gene Therapies, Inc.盘中异动 大幅上涨5.88%报1.80美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517616939","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517616939?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:31","pubTimestamp":1741271471,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时31分，Taysha Gene Therapies, Inc.股票出现波动，股价快速上涨5.88%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.63%。其相关个股中，Plus Therapeutics, Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Exicure, Inc.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为920.19%、96.25%、45.65%，振幅较大的相关个股有Astria Therapeutics, Inc.、Mbx Biosciences, Inc.、Plus Therapeutics, Inc.，振幅分别为10.59%、8.18%、8.11%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223111989eb3dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223111989eb3dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517469979","title":"Taysha Gene Therapies, Inc.盘中异动 早盘快速拉升5.21%报1.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517469979","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517469979?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:38","pubTimestamp":1741189099,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时38分，Taysha Gene Therapies, Inc.股票出现波动，股价快速上涨5.21%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体涨幅为1.29%。其相关个股中，Chimerix, Inc.、Nutriband Inc C/Wts 、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为867.88%、286.98%、264.83%，振幅较大的相关个股有Klotho Neurosciences Inc C/Wts 21/06/2029 、Nkgen Biotech, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 ，振幅分别为54.27%、42.66%、41.26%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233820989d56ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305233820989d56ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516074548","title":"Taysha Gene Therapies, Inc.2024财年实现净利润-89.30百万美元，同比增加20.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516074548","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516074548?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:00","pubTimestamp":1740931248,"startTime":"0","endTime":"0","summary":"3月3日，Taysha Gene Therapies, Inc.公布财报，公告显示公司2024财年净利润为-89.30百万美元，同比增加20.27%；其中营业收入为8.33百万美元，同比减少46.08%，每股基本收益为-0.36美元。机构评级：截至2025年3月3日，当前有11家机构对Taysha Gene Therapies, Inc.目标价做出预测，其中目标均价为6.59美元，其中最低目标价为5.00美元，最高目标价为8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000116abe4acb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000116abe4acb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514385169","title":"Taysha Gene Therapies, Inc.盘中异动 早盘急速上涨6.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385169?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:42","pubTimestamp":1740667327,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时42分，Taysha Gene Therapies, Inc.股票出现异动，股价快速上涨6.17%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体涨幅为0.62%。其相关个股中，Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pasithea Therapeutics Corp C/Wts 12/08/2026 涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为453.66%、94.10%、78.91%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Channel Therapeutics Corporation，振幅分别为41.12%、21.99%、16.89%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272242079632b347&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272242079632b347&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514891248","title":"Chardan Capital：维持Taysha Gene Therapies(TSHA.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至7.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891248","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514891248?lang=zh_cn&edition=full","pubTime":"2025-02-27 06:53","pubTimestamp":1740610401,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Taysha Gene Therapies(TSHA.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至7.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27065348414433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135489441","title":"泰莎基因治疗公司第四季度每股收益$(0.07) 优于预期$(0.08)，销售额$202万低于预期$231万","url":"https://stock-news.laohu8.com/highlight/detail?id=1135489441","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135489441?lang=zh_cn&edition=full","pubTime":"2025-02-26 21:07","pubTimestamp":1740575243,"startTime":"0","endTime":"0","summary":"泰莎基因治疗公司公布其季度每股亏损$，优于分析师一致预期的$，超出预期12.5%。与去年同期每股收益$0.92相比，本次为107.61%的下降。公司报告季度销售额为$202万，低于分析师预期的$231万，差距为12.43%。以上内容来自Benzinga Earnings专栏，原文如下：Taysha Gene Therapies  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 12.5 percent. This is a 107.61 percent decrease over earnings of $0.92 per share from the same period last year.  The company reported quarterly sales of $2.02 million which missed the analyst consensus estimate of $2.31 million by 12.43 perce","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰莎基因治疗公司第四季度每股收益$(0.07) 优于预期$(0.08)，销售额$202万低于预期$231万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514895011","title":"Taysha Gene Therapies, Inc.盘中异动 早盘快速上涨5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514895011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514895011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:07","pubTimestamp":1740499678,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时07分，Taysha Gene Therapies, Inc.股票出现异动，股价大幅拉升5.15%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1243.17%、1101.03%、842.47%，振幅较大的相关个股有Organovo Holdings, Inc.、Silexion Therapeutics Corp、Adial Pharmaceuticals, Inc，振幅分别为224.93%、87.83%、64.05%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226000758a2539d5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226000758a2539d5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512657561","title":"Taysha Gene Therapies, Inc.盘中异动 急速上涨5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512657561","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512657561?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:34","pubTimestamp":1739889255,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时34分，Taysha Gene Therapies, Inc.股票出现波动，股价快速上涨5.52%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Aditxt, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为282.11%、98.62%、74.41%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Allogene Therapeutics, Inc.、Glycomimetics, Inc.，振幅分别为34.04%、22.30%、18.69%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223415abd3afcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223415abd3afcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511699876","title":"Taysha Gene Therapies, Inc.盘中异动 股价大涨6.17%报1.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511699876","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511699876?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:47","pubTimestamp":1739544427,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时47分，Taysha Gene Therapies, Inc.股票出现异动，股价快速上涨6.17%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1778.14%、471.05%、415.00%，振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.，振幅分别为66.93%、32.93%、32.49%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422470796231f04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021422470796231f04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510738099","title":"Taysha Gene Therapies, Inc.盘中异动 股价大跌5.35%报1.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510738099","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510738099?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:34","pubTimestamp":1739284477,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时34分，Taysha Gene Therapies, Inc.股票出现异动，股价大幅下挫5.35%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.96%。其相关个股中，Lipella Pharmaceuticals Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、In8Bio, Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.较为活跃，换手率分别为2043.67%、539.47%、179.10%，振幅较大的相关个股有In8Bio, Inc.、Ocean Biomedical, Inc.、知临集团，振幅分别为25.06%、22.23%、16.57%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223438a241fbb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223438a241fbb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510589104","title":"Taysha Gene Therapies, Inc.盘中异动 下午盘快速拉升5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510589104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510589104?lang=zh_cn&edition=full","pubTime":"2025-02-11 03:32","pubTimestamp":1739215955,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日03时32分，Taysha Gene Therapies, Inc.股票出现波动，股价大幅拉升5.14%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体跌幅为0.83%。其相关个股中，Dominari Holdings Inc.、Biodexa Pharmaceuticals Plc、知临集团涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为3141.87%、1673.72%、1415.92%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Biodexa Pharmaceuticals Plc、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为99.86%、92.63%、87.80%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211033236961e37d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211033236961e37d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509440597","title":"Taysha Gene Therapies, Inc.盘中异动 股价大涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509440597","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509440597?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:41","pubTimestamp":1738939304,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时41分，Taysha Gene Therapies, Inc.股票出现异动，股价急速拉升5.12%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Conduit Pharmaceuticals Inc.、Lipella Pharmaceuticals Inc.、Aditxt, Inc.较为活跃，换手率分别为1935.33%、53.18%、38.77%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、180 Life Sciences Corp C/Wts 07/11/2025，振幅分别为130.43%、50.97%、20.91%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207224144961b3ac7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207224144961b3ac7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509023175","title":"Taysha Gene Therapies, Inc.盘中异动 快速上涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509023175","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509023175?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:19","pubTimestamp":1738775981,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时19分，Taysha Gene Therapies, Inc.股票出现异动，股价急速拉升5.10%。Taysha Gene Therapies, Inc.股票所在的生物技术行业中，整体涨幅为1.99%。其相关个股中，Transcode Therapeutics, Inc.、Pasithea Therapeutics Corp.、Apollomics Inc C/Wts 01/04/2028 涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4480.06%、2151.56%、1511.17%，振幅较大的相关个股有Transcode Therapeutics, Inc.、Oragenics Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 ，振幅分别为99.51%、97.43%、59.58%。Taysha Gene Therapies, Inc.公司简介：Taysha Gene Therapies Inc是一家以患者为中心的基因治疗公司，旨在消除单基因CNS疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206011941987b976b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206011941987b976b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":0.0515},{"period":"1month","weight":0.1476},{"period":"3month","weight":0.4943},{"period":"6month","weight":0.2438},{"period":"1year","weight":1.6872},{"period":"ytd","weight":0.1873}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Taysha Gene Therapies, Inc.最初是根据德克萨斯州法律于2019年9月20日成立。该公司于2020年2月13日转换为特拉华州公司。该公司是一家以患者为中心的基因治疗公司，致力于开发和开发商业化基于AAV的基因疗法，用于治疗罕见和大量患者群体的中枢神经系统单基因疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177745},{"month":2,"riseRate":0.5,"avgChangeRate":0.091899},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104956},{"month":4,"riseRate":0.5,"avgChangeRate":0.079391},{"month":5,"riseRate":0.333333,"avgChangeRate":0.032889},{"month":6,"riseRate":0.333333,"avgChangeRate":0.002069},{"month":7,"riseRate":0.5,"avgChangeRate":0.009236},{"month":8,"riseRate":0.8,"avgChangeRate":0.75256},{"month":9,"riseRate":0.2,"avgChangeRate":-0.089587},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Taysha Gene Therapies, Inc.(TSHA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Taysha Gene Therapies, Inc.(TSHA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}